Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
Status:
Withdrawn
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various
solid tumor types. The study seeks to determine a safe dose of the combination of study drugs
and then examine this dose in larger groups of patients of specific tumor types to evaluate
its anti-tumor efficacy. Treatment will continue in patients who respond for up to 1 year.